<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01564017</url>
  </required_header>
  <id_info>
    <org_study_id>BIA--DPT-P2-001</org_study_id>
    <secondary_id>2011-004583-30</secondary_id>
    <nct_id>NCT01564017</nct_id>
  </id_info>
  <brief_title>Dose-response Study With Subcutaneous Immunotherapy of an Standardized Dermatophagoides Pteronyssinus (DPT) Extract</brief_title>
  <official_title>Phase II, Multicenter, Randomized, Double-blind Study, With Subcutaneous Immunotherapy, in Parallel Groups and Placebo-controlled, in Patients With Rhinoconjunctivitis ± Asthma Sensitized to Dermatophagoides Pteronyssinus.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Roxall Medicina España S.A</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Roxall Medicina España S.A</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      As part of the registration plan of our products and after performing a Phase I study the
      present trial has been designed to compare the efficacy of 5 different doses of subcutaneous
      immunotherapy in depot presentation.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2012</start_date>
  <completion_date type="Actual">May 2013</completion_date>
  <primary_completion_date type="Actual">May 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Changes in nasal provocation test</measure>
    <time_frame>from baseline (V0) to final visit (VF 18 weeks after randmization)</time_frame>
    <description>Variation of the concentration of DPT extract needed to produce a positive nasal provocation test from baseline (V0) to final visit (FV). The changes will be compared among groups (including the placebo group).</description>
  </primary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Allergic Rhinoconjunctivitis</condition>
  <arm_group>
    <arm_group_label>Allergovac depot. Group 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing dosages till the maintenance dose of 0.0625 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac depot. Group 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing dosages till the maintenance dose of 0.125 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac depot. Group 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing dosages till the maintenance dose of 0.25 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac depot. Group 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing dosages till the maintenance dose of 0.5 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac depot. Group 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Increasing dosages till the maintenance dose of 0.75 SPT is reached. Afterwards, 3 maintenance doses are given at 4-weekly intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Allergovac depot placebo. Group 6</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The same scheme of treatment as the active groups</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac depot</intervention_name>
    <description>Depot sterile suspension fpor subcutaneous injection
Increasing concentrations to reach the following maintenance doses:
Group 1: 0.25 SPT</description>
    <arm_group_label>Allergovac depot. Group 1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac depot</intervention_name>
    <description>Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 2: 0.5 SPT</description>
    <arm_group_label>Allergovac depot. Group 2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac depot</intervention_name>
    <description>Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 3: 1 SPT</description>
    <arm_group_label>Allergovac depot. Group 3</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac depot</intervention_name>
    <description>depot sterile suspension for subcutaneous injection
Increasing concentrations to reach the following maintenance doses:
Group 4: 2 SPT</description>
    <arm_group_label>Allergovac depot. Group 4</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac depot</intervention_name>
    <description>Depot sterile suspension for subcutaneous injection.
Increasing concentrations to reach the following maintenance doses:
Group 5: 4 SPT</description>
    <arm_group_label>Allergovac depot. Group 5</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Allergovac depot</intervention_name>
    <description>Sterile suspension for subcutaneous injection.
Same number of administration as the active groups</description>
    <arm_group_label>Allergovac depot placebo. Group 6</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients must sign the Informed Consent Form.

          2. Patients must be between 18 and 60 years of age.

          3. Patients with perennial allergic rhinoconjunctivitis produced by Dermatophagoides
             pteronyssinus during at least 2 years prior to participating in the study. Although
             the pathology being studied is allergic rhinoconjunctivitis, patients who have
             concomitant mild or moderate asthma may be included.

          4. Patients who have had a skin prick test result greater or equal to 3 mm in diameter
             against Dermatophagoides pteronyssinus.

          5. Patients who have specific Immunoglobulin E (IgE) greater or equal to class 2
             (CAP/PHADIA) to Dermatophagoides pteronyssinus.

          6. Patients will preferably be monosensitized to Dermatophagoides pteronyssinus.
             Polysensitized patients may only be included in the study if their other
             sensitizations are produced by:

               -  Pollens whose season period does not overlap with the study treatment or, if
                  overlap, whose specific IgE levels are less than class 2.

               -  Perennial allergens with specific IgE levels less than class 2.

               -  Allergens that do not cohabit with the patient or whose environmental levels are
                  not high enough to produce symptoms during the study period.

          7. Women of child-bearing potential must have a negative urine pregnancy test at the time
             they begin the study.

          8. Furthermore, women of child-bearing potential must agree to use adequate contraceptive
             methods during this study if they are sexually active.

        Exclusion Criteria:

          1. Patients with stable and continued use of medication to treat their allergic condition
             during the 2 weeks prior to their inclusion in the study.

          2. Patients sensitized and with specific IgE levels greater or equal to class 2 to other
             perennial or seasonal allergens clinically relevant including other mites unless they
             are cross reactive with Dermatophagoides pteronyssinus.

          3. Patients who have received immunotherapy in the 5 years prior to the study against
             either the allergen being tested or an allergen which is cross-reactive, or who are
             currently receiving immunotherapy for any other allergen.

          4. Patients with severe asthma or FEV1&lt; 70% or with asthma which requires treatment with
             inhaled or systemic corticoids at the time of the study or in the 8 weeks immediately
             prior to the onset of treatment.

          5. Patients with immunological, cardiac, renal or hepatic diseases or with any other
             illness which the investigators deem may interfere with the study.

          6. Patients with a prior history of anaphylaxis.

          7. Patients with chronic urticaria.

          8. Patients with moderate-severe atopic dermatitis.

          9. Patients with clinically relevant malformations of the upper respiratory tract.

         10. Patients who have participated in another clinical trial within 3 months prior to this
             study.

         11. Patients being treated with tricyclic antidepressants, psychotropic drugs,
             beta-blockers, or angiotensin-converting enzyme inhibitors (ACEIs).

         12. Women who are pregnant or breast-feeding or are of child-bearing age and who do not
             agree to use adequate contraception if they are sexually active and who have not
             demonstrated that they have been surgically sterilized or have other means of not
             bearing children.

         13. Patients who cannot attend study visits.

         14. Patients who are uncooperative or refuse to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fernando Rodríguez, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ramón Lleonart, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario Marqués de Valdecilla</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert Roger, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Germans Trias i Pujol Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Dolores Hernández, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Universitario La Fe</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Vidal, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario de Santiago</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Juan A Pagán, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Virgen de la Arrixaca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Carmen Marcos, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Xeral de Vigo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jose A Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Donostia</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Victoria Moreno, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Blanca Paloma</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Luis A Navarro, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Luis Alcañiz</affiliation>
  </overall_official>
  <overall_official>
    <last_name>María I Peña, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Vega Baja</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Marta Alvariño, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital de Manises</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Vega Baja</name>
      <address>
        <city>Orihuela</city>
        <state>Alicante</state>
        <zip>03314</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Triasl i Pujol</name>
      <address>
        <city>Badalona</city>
        <state>Barcelona</state>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Donostia</name>
      <address>
        <city>Donostia-San Sebastián</city>
        <state>Guipuzcoa</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>La Coruña</state>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Arrixaca</name>
      <address>
        <city>El Palmar</city>
        <state>Murcia</state>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Xeral de Vigo</name>
      <address>
        <city>Vigo</city>
        <state>Pontevedra</state>
        <zip>36024</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Manises</name>
      <address>
        <city>Manises</city>
        <state>Valencia</state>
        <zip>46940</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Luis Alcañiz</name>
      <address>
        <city>Xátiva</city>
        <state>Valencia</state>
        <zip>46800</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari de Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Blanca Paloma</name>
      <address>
        <city>Huelva</city>
        <zip>21005</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marqués de Valdecilla</name>
      <address>
        <city>Santander</city>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitari i Politècnic La Fe</name>
      <address>
        <city>Valencia</city>
        <zip>46026</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 23, 2012</study_first_submitted>
  <study_first_submitted_qc>March 26, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 27, 2012</study_first_posted>
  <last_update_submitted>April 28, 2017</last_update_submitted>
  <last_update_submitted_qc>April 28, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergy</keyword>
  <keyword>Allergic rhinoconjunctivitis</keyword>
  <keyword>Immunotherapy</keyword>
  <keyword>D. pteronyssinus</keyword>
  <keyword>house dust allergy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Conjunctivitis</mesh_term>
    <mesh_term>Conjunctivitis, Allergic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

